Moderna, Immatics Ink Strategic Multi-Platform Collaboration To Develop Oncology Therapeutics

(RTTNews) - Biopharmaceutical company Moderna, Inc. (MRNA) and Germany-based Immatics N.V. (IMTX) announced Monday a strategic research and development collaboration to pioneer novel and transformative therapies for cancer patients with high unmet medical need.

This broad multi-platform collaboration will leverage the deep scientific expertise and core operational capabilities of both companies, combining Immatics' TCR platform with Moderna's cutting-edge mRNA technology, and span various therapeutic modalities including bispecifics, cell therapy and cancer vaccines.